Article Text
Letters
Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab
Statistics from Altmetric.com
Footnotes
-
Funding This study was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation.
-
Competing interests AO has received consultant fees from Chugai Pharmaceutical, the manufacture of tocilizumab.
-
Patient consent Obtained.
-
Ethics approval This study was conducted with approval of the Human Research and Ethics Committees at Osaka University Hospital.
-
Provenance and peer review Not commissioned; externally peer reviewed.